<p class="jove_content">To expand the ability of laboratories worldwide to assess the eligibility of patients with lung cancer for treatment with pembrolizumab, in a reliable and reproducible manner, we developed an assay that uses the 22C3 antibody concentrate on a widely available immunohistochemical autostainer, for both biopsy and cytology specimens.</p>

using-22c3-anti-pd-l1-antibody-concentrate-on-biopsy-cytology-samples

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Pembrolizumab monotherapy has been approved for the first- and second-line treatment of patients with PD-L1-expressing advanced non-small cell lung cancer ...

Laboratory of Clinical and Experimental Pathology

Pasteur Hospital

Hospital University Federation OncoAge

Institute for Research on Cancer and Aging in Nice (Inserm U1081 and CNRS 7284)

Hospital-Integrated Biobank (BB-0033-00025)

Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Hospital University Federation OncoAge

Hospital-Integrated Biobank (BB-0033-00025), Pasteur Hospital

Université Côte d’Azur

Institution - Université Côte d’Azur

Articles Published in JoVE